OptiNose, Inc. (NASDAQ:OPTN) Short Interest Update

OptiNose, Inc. (NASDAQ:OPTN) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 247,800 shares, an increase of 16.2% from the January 15th total of 213,300 shares. Currently, 3.1% of the company’s shares are short sold. Based on an average daily trading volume, of 65,200 shares, the short-interest ratio is currently 3.8 days.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Lake Street Capital decreased their price target on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, January 16th. Piper Sandler dropped their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Finally, HC Wainwright upped their price target on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

Hedge Funds Weigh In On OptiNose

Several institutional investors and hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new stake in OptiNose during the 3rd quarter valued at $61,000. State Street Corp lifted its position in OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after acquiring an additional 42,500 shares during the period. Rice Hall James & Associates LLC increased its stake in OptiNose by 15.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock valued at $764,000 after purchasing an additional 152,435 shares in the last quarter. Geode Capital Management LLC increased its stake in OptiNose by 33.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock valued at $870,000 after purchasing an additional 326,918 shares in the last quarter. Finally, Easterly Investment Partners LLC grew its stake in shares of OptiNose by 5.0% in the third quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock worth $1,581,000 after acquiring an additional 113,015 shares during the period. Institutional investors own 85.60% of the company’s stock.

OptiNose Trading Up 6.8 %

Shares of NASDAQ:OPTN traded up $0.38 during trading on Friday, reaching $6.00. The company had a trading volume of 23,563 shares, compared to its average volume of 47,458. The company has a fifty day moving average of $6.23 and a two-hundred day moving average of $9.61. The stock has a market capitalization of $60.36 million, a P/E ratio of -1.43 and a beta of -0.17. OptiNose has a 12 month low of $4.82 and a 12 month high of $31.50.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.